CA2603298A1 - Vaccin contre la tuberculose et sa methode de fabrication - Google Patents

Vaccin contre la tuberculose et sa methode de fabrication Download PDF

Info

Publication number
CA2603298A1
CA2603298A1 CA002603298A CA2603298A CA2603298A1 CA 2603298 A1 CA2603298 A1 CA 2603298A1 CA 002603298 A CA002603298 A CA 002603298A CA 2603298 A CA2603298 A CA 2603298A CA 2603298 A1 CA2603298 A1 CA 2603298A1
Authority
CA
Canada
Prior art keywords
bcg
seq
nucleic acid
tuberculosis
mpb70
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603298A
Other languages
English (en)
Inventor
Marcel Behr
Serge Mostowy
Danielle Charlet
David Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603298A1 publication Critical patent/CA2603298A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002603298A 2005-04-01 2006-04-03 Vaccin contre la tuberculose et sa methode de fabrication Abandoned CA2603298A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66724305P 2005-04-01 2005-04-01
US60/667,243 2005-04-01
PCT/CA2006/000503 WO2006102767A1 (fr) 2005-04-01 2006-04-03 Vaccin contre la tuberculose et sa methode de fabrication

Publications (1)

Publication Number Publication Date
CA2603298A1 true CA2603298A1 (fr) 2006-10-05

Family

ID=37052924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603298A Abandoned CA2603298A1 (fr) 2005-04-01 2006-04-03 Vaccin contre la tuberculose et sa methode de fabrication

Country Status (3)

Country Link
EP (1) EP1863914A1 (fr)
CA (1) CA2603298A1 (fr)
WO (1) WO2006102767A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2696891B1 (fr) 2011-04-11 2019-06-26 Alarum Development Ltd Nouveaux vaccins destinés à la prévention et au traitement de la tuberculose
EP2754452A1 (fr) 2013-01-09 2014-07-16 LIONEX Diagnostics and Therapeutics GmbH SigC pour la modulation de réponses immunitaires
JP7035063B2 (ja) * 2017-04-07 2022-03-14 ジュン・リウ phoP-phoRを過剰発現する組換えBCG

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693500A (en) * 1988-03-31 1997-12-02 Commonwealth Scientific And Industrial Research Organisation Diagnosis of Mycobacterium bovis infection
JPH02195895A (ja) * 1989-01-24 1990-08-02 Ajinomoto Co Inc Bcg菌由来免疫タンパクmpb70
EP1401866A2 (fr) * 2001-02-22 2004-03-31 Institut Pasteur Analyse comparative des genomes de mycobacteries en vue de l'identification de cibles a des fins de diagnostic, de prophylaxie ou de traitement de mycobacterioses

Also Published As

Publication number Publication date
WO2006102767A1 (fr) 2006-10-05
EP1863914A1 (fr) 2007-12-12

Similar Documents

Publication Publication Date Title
Charlet et al. Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK
JP4053085B2 (ja) マイコバクテリアの膜−関連免疫原
US11717565B2 (en) Recombinant BCG overexpressing phoP-phoR
TWI334884B (en) Anti-bacterial vaccine compositions
EP1492867A2 (fr) Identification des regions rd1 et rd5 associees a la virulence afin de permettre le developpement des vaccins ameliores de m. bovis bcg et m. microti
Matsumoto et al. Cloning and sequencing of a unique antigen MPT70 from Mycobacterium tuberculosis H37Rv and expression in BCG using E. coli‐mycobacteria shuttle vector
US20150240201A1 (en) Modified bcg strains with reduced or eliminated activity of lsr2 and pharmaceutical composition comprising same
WO2011130878A9 (fr) Vaccins contre la tuberculose comprenant des souches recombinantes de bcg surexprimant phop et/ou une ou des protéines du régulon de phop
CA2603298A1 (fr) Vaccin contre la tuberculose et sa methode de fabrication
EP1348036A2 (fr) Protection contre les infections mycobacteriennes
US10010597B2 (en) Recombinant Mycobacterium bovis BCG expressing antigens of the Mycobacterium marinum ESX-1 secretion system
US20040219585A1 (en) Nontypeable haemophilus influenzae virulence factors
JP5994127B2 (ja) 新規な組換えbcgワクチン
EP0707496A1 (fr) PROCEDES ET COMPOSITIONS DE DETECTION ET DE TRAITEMENT DES INFECTIONS MYCOBACTERIENNES AU MOYEN D'UN GENE inhA
Eroshenko et al. Sequence analysis of the yadA, inv, and ail genes and their expression in the main and nonmain Yersinia pestis subspecies and Yersinia pseudotuberculosis
US20220339275A1 (en) Vaccine
JP2002534960A (ja) ワクチン
WO2002067982A2 (fr) Methodes et compositions d'intervention therapeutique dans le cadre d'une maladie infectieuse
Charlet et al. " Department of Medicine, Division of Experimental Medicine, McGill University.“Department of Microbiology and Immunology, McGill University.
Cole et al. Dissection of ESAT-6 System 1 of
Schnappinger Transcriptomics and Transcriptional Regulation
Dubail et al. The Sortase SrtA of

Legal Events

Date Code Title Description
FZDE Discontinued